Lenvatinib with pembrolizumab for untreated advanced renal cell carcinoma
Technology appraisal guidance
Reference number: TA858
Published:
Due to operational challenges, the second committee meeting has been cancelled. We are exploring options to continue the appraisal and will provide an update shortly.